Caris filed suit asserting that Foundation Medicine 2019s FoundationOne 00ae, FoundationOne 00ae Heme, and FoundationACT 00ae products infringe five Caris patents covering systems for generating reports identifying therapeutic agents for cancer treatment based on molecular profiles of the tumor. Caris alleges willful infringement, citing to statements in Foundation 2019s 10-K SEC filings that identify Caris as a direct competitor and that indicates that competitors 201cmay also use their patent portfolios, developed in connection with developing their tests, to allege that [Defendant 2019s] products infringe their patents, and [Defendant] could face litigation with respect to such allegations and the validity of such patents. 201d
By submitting this form, you are consenting to receive marketing emails from: Lando & Anastasi, LLP. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact
SHARE THIS POST
